Curcumin Analogs in Glioblastoma Therapy: A Narrative Review

Area of Science:

• Neuro-oncology
• Pharmacology
• Molecular Biology

Background:

• Glioblastoma (GBM) is an aggressive brain tumor with poor prognosis, limited by treatment resistance and Blood-Brain Barrier (BBB) penetration.
• Conventional therapies face challenges due to tumor heterogeneity and drug resistance, necessitating novel multi-targeted strategies.

Purpose of the Study:

• To review the therapeutic potential of curcumin analogs in GBM.
• To focus on their molecular mechanisms, in silico predictions, preclinical efficacy, and synergistic potential with standard treatments.

Main Methods:

• Comprehensive literature search of in vitro, in vivo, and computational studies on curcumin analogs.
• Analysis of mechanistic investigations including apoptosis, cell-cycle arrest, autophagy, ferroptosis, and inhibition of oncogenic pathways (STAT3, NF-κB, PI3K/Akt/mTOR, EGFR).
• Assessment of pharmacokinetic optimization and BBB permeability.

Main Results:

• Curcumin analogs exhibit enhanced cytotoxicity in GBM cells, including temozolomide-resistant lines, via multi-target modulation.
• In silico studies show strong binding to GBM-relevant targets.
• Preclinical studies demonstrate tumor growth suppression, inhibited angiogenesis, and prolonged survival with analogs like C-150, ALZ003, and DMC-BH.
• Synergistic anti-tumor effects observed when combined with temozolomide, radiotherapy, or anti-angiogenic agents.

Conclusions:

• Curcumin analogs are promising multi-targeted agents for GBM, addressing heterogeneity, resistance, and invasiveness.
• Optimization of pharmacokinetics and targeted delivery is crucial for clinical translation.
• Further clinical evaluation is necessary to establish curcumin analogs as effective GBM therapies.